Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank86
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-12.90M
↑ 88% vs avg
Percentile
P86
Within normal range
Streak
4 yr
Consecutive growthExpanding
Average
$-110.88M
Historical baseline
PeriodValueYoY Change
2025$-12.90M+46.2%
2024$-23.97M+82.3%
2023$-135.49M+22.5%
2022$-174.83M+33.7%
2021$-263.81M-167.7%
2020$-98.55M-38.2%
2019$-71.29M+52.1%
2018$-148.79M-13.3%
2017$-131.32M-174.6%
2016$-47.82M-